{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:40:30Z","timestamp":1790710830457,"version":"4.1.0"},"publisher-location":"New York, NY","reference-count":59,"publisher":"Springer New York","isbn-type":[{"value":"9781493991440","type":"print"},{"value":"9781493991457","type":"electronic"}],"license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019]]},"DOI":"10.1007\/978-1-4939-9145-7_10","type":"book-chapter","created":{"date-parts":[[2019,3,25]],"date-time":"2019-03-25T16:08:22Z","timestamp":1553530102000},"page":"151-162","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["3D-3 Tumor Models in Drug Discovery for Analysis of Immune Cell Infiltration"],"prefix":"10.1007","author":[{"given":"Annika","family":"Osswald","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viola","family":"Hedrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Sommergruber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,26]]},"reference":[{"key":"10_CR1","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","volume":"100","author":"D Hanahan","year":"2000","unstructured":"Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57\u201370","journal-title":"Cell"},{"key":"10_CR2","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646\u2013674","journal-title":"Cell"},{"key":"10_CR3","first-page":"1016","volume":"7","author":"YA Fouad","year":"2017","unstructured":"Fouad YA, Aanei C (2017) Revisiting the hallmarks of cancer. Am J Cancer Res 7:1016\u20131036","journal-title":"Am J Cancer Res"},{"key":"10_CR4","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1146\/annurev.immunol.22.012703.104803","volume":"22","author":"GP Dunn","year":"2004","unstructured":"Dunn GP, Old LJ, Schreiber RD (2004) The three Es of cancer immunoediting. Annu Rev Immunol 22:329\u2013360","journal-title":"Annu Rev Immunol"},{"key":"10_CR5","doi-asserted-by":"publisher","first-page":"5593","DOI":"10.21873\/anticanres.11144","volume":"36","author":"A Sukari","year":"2016","unstructured":"Sukari A, Nagasaka M, Al-Hadidi A et al (2016) Cancer immunology and immunotherapy. Anticancer Res 36:5593\u20135606","journal-title":"Anticancer Res"},{"key":"10_CR6","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1172\/JCI31405","volume":"117","author":"JB Swann","year":"2007","unstructured":"Swann JB, Smyth MJ (2007) Immune surveillance of tumors. J Clin Invest 117:1137\u20131146","journal-title":"J Clin Invest"},{"key":"10_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2018.00414","volume":"9","author":"L Ziani","year":"2018","unstructured":"Ziani L, Chouaib S, Thiery J (2018) Alteration of the antitumor immune response by cancer-associated fibroblasts. Front Immunol 9:1\u201314","journal-title":"Front Immunol"},{"key":"10_CR8","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ccr.2009.12.041","volume":"17","author":"N Erez","year":"2010","unstructured":"Erez N, Truitt M, Olson P et al (2010) Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaB-dependent manner. Cancer Cell 17:135\u2013147","journal-title":"Cancer Cell"},{"key":"10_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0124283","volume":"10","author":"A Rudisch","year":"2015","unstructured":"Rudisch A, Dewhurst MR, Horga LG et al (2015) High EMT signature score of invasive non-small cell lung cancer (NSCLC) cells correlates with NF\u03baB driven colony-stimulating factor 2 (CSF2\/GM-CSF) secretion by neighboring stromal fibroblasts. PLoS One 10:e0124283","journal-title":"PLoS One"},{"key":"10_CR10","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12:252\u2013264","journal-title":"Nat Rev Cancer"},{"key":"10_CR11","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.coph.2018.02.006","volume":"40","author":"A Bianco","year":"2018","unstructured":"Bianco A, Malapelle U, Rocco D et al (2018) Targeting immune checkpoints in non-small cell lung cancer. Curr Opin Pharmacol 40:46\u201350","journal-title":"Curr Opin Pharmacol"},{"key":"10_CR12","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s11912-018-0676-z","volume":"20","author":"M Furue","year":"2018","unstructured":"Furue M, Ito T, Wada N et al (2018) Melanoma and immune checkpoint inhibitors. Curr Oncol Rep 20:29","journal-title":"Curr Oncol Rep"},{"key":"10_CR13","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ctrv.2018.02.002","volume":"64","author":"J Remon","year":"2018","unstructured":"Remon J, Vilari\u00f1o N, Reguart N (2018) Immune checkpoint inhibitors in non-small cell lung cancer (NSCLC): approaches on special subgroups and unresolved burning questions. Cancer Treat Rev 64:21\u201329","journal-title":"Cancer Treat Rev"},{"key":"10_CR14","doi-asserted-by":"publisher","first-page":"101","DOI":"10.5152\/TurkThoracJ.2017.17006","volume":"18","author":"SN Kazaz","year":"2017","unstructured":"Kazaz SN, \u00d6ztop I (2017) Immune checkpoint inhibitors in advanced-stage non-small cell lung cancer. Turk Thorac J 18:101\u2013107","journal-title":"Turk Thorac J"},{"key":"10_CR15","first-page":"61","volume":"22","author":"I Lugowska","year":"2018","unstructured":"Lugowska I, Teterycz P, Rutkowski P (2018) Immunotherapy of melanoma. Contemp Oncol (Pozn) 22:61\u201367","journal-title":"Contemp Oncol (Pozn)"},{"key":"10_CR16","doi-asserted-by":"crossref","unstructured":"Rausch MP, Hastings KT (2017) Immune checkpoint inhibitors in the treatment of melanoma: from basic science to clinical application. In: Ward WH, Farma JM (eds) Cutaneous melanoma: etiology and therapy. Codon Publications, Brisbane. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK481851\/","DOI":"10.15586\/codon.cutaneousmelanoma.2017.ch9"},{"key":"10_CR17","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1002\/cncr.31043","volume":"124","author":"RN Pillai","year":"2018","unstructured":"Pillai RN, Behera M, Owonikoko TK et al (2018) Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: a systematic analysis of the literature. Cancer 124:271\u2013277","journal-title":"Cancer"},{"key":"10_CR18","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1093\/annonc\/mdx286","volume":"28","author":"L Khoja","year":"2017","unstructured":"Khoja L, Day D, Wei-Wu Chen T et al (2017) Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann Oncol 28:2377\u20132385","journal-title":"Ann Oncol"},{"key":"10_CR19","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1242\/jcs.115.1.39","volume":"115","author":"T Gudjonsson","year":"2002","unstructured":"Gudjonsson T, R\u00f8nnov-Jessen L, Villadsen R et al (2002) Normal and tumor-derived myoepithelial cells differ in their ability to interact with luminal breast epithelial cells for polarity and basement membrane deposition. J Cell Sci 115:39\u201350","journal-title":"J Cell Sci"},{"issue":"12","key":"10_CR20","doi-asserted-by":"publisher","first-page":"e1701405","DOI":"10.1002\/adhm.201701405","volume":"7","author":"A Pupovac","year":"2018","unstructured":"Pupovac A, Senturk B, Griffoni C et al (2018) Toward immunocompetent 3D skin models. Adv Healthc Mater 7(12):e1701405","journal-title":"Adv Healthc Mater"},{"key":"10_CR21","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.biomaterials.2017.10.002","volume":"154","author":"P Zhuang","year":"2018","unstructured":"Zhuang P, Sun AX, An J et al (2018) 3D neural tissue models: from spheroids to bioprinting. Biomaterials 154:113\u2013133","journal-title":"Biomaterials"},{"key":"10_CR22","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s40139-016-0111-9","volume":"4","author":"MG Francipane","year":"2016","unstructured":"Francipane MG, Lagasse E (2016) Towards organs on demand: breakthroughs and challenges in models of organogenesis. Curr Pathobiol Rep 4:77\u201385","journal-title":"Curr Pathobiol Rep"},{"key":"10_CR23","doi-asserted-by":"publisher","first-page":"1700268","DOI":"10.1002\/biot.201700341","volume":"13","author":"K Zscheppang","year":"2018","unstructured":"Zscheppang K, Berg J, Hedtrich S et al (2018) Human pulmonary 3D models for translational research. Biotechnol J 13:1700268","journal-title":"Biotechnol J"},{"key":"10_CR24","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1039\/C6IB00039H","volume":"8","author":"EL Jackson","year":"2016","unstructured":"Jackson EL, Lu H (2016) Three-dimensional models for studying development and disease: moving on from organisms to organs-on-a-chip and organoids. Integr Biol (Camb) 8:672\u2013683","journal-title":"Integr Biol (Camb)"},{"issue":"4","key":"10_CR25","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/j.biotechadv.2018.03.009","volume":"36","author":"M Sreepadmanabh","year":"2018","unstructured":"Sreepadmanabh M, Toley BJ (2018) Investigations into the cancer stem cell niche using in-vitro 3-D tumor models and microfluidics. Biotechnol Adv 36(4):1094\u20131110","journal-title":"Biotechnol Adv"},{"key":"10_CR26","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.jcmgh.2017.12.004","volume":"5","author":"L Moreira","year":"2017","unstructured":"Moreira L, Bakir B, Chatterji P et al (2017) Pancreas 3D organoids: current and future aspects as a research platform for personalized medicine in pancreatic cancer. Cell Mol Gastroenterol Hepatol 5:289\u2013298","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"8","key":"10_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.201701174","volume":"7","author":"D Rodenhizer","year":"2018","unstructured":"Rodenhizer D, Dean T, D\u2019Arcangelo E et al (2018) The current landscape of 3D in vitro tumor models: what cancer hallmarks are accessible for drug discovery? Adv Healthc Mater 7(8):e1701174","journal-title":"Adv Healthc Mater"},{"key":"10_CR28","doi-asserted-by":"crossref","unstructured":"Hoarau-V\u00e9chot J, Rafii A, Touboul C et al (2018) Halfway between 2D and animal models: are 3D cultures the ideal tool to study cancer-microenvironment interactions? Int J Mol Sci 19(1):1\u201324","DOI":"10.3390\/ijms19010181"},{"key":"10_CR29","doi-asserted-by":"publisher","first-page":"3760","DOI":"10.1039\/C7LC00574A","volume":"17","author":"D Caballero","year":"2017","unstructured":"Caballero D, Blackburn SM, de Pablo M et al (2017) Tumour-vessel-on-a-chip models for drug delivery. Lab Chip 17:3760\u20133771","journal-title":"Lab Chip"},{"key":"10_CR30","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.chembiol.2017.06.012","volume":"24","author":"F Weeber","year":"2017","unstructured":"Weeber F, Ooft SN, Dijkstra KK et al (2017) Tumor organoids as a pre-clinical cancer model for drug discovery. Cell Chem Biol 24:1092\u20131100","journal-title":"Cell Chem Biol"},{"key":"10_CR31","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3389\/fphar.2018.00006","volume":"9","author":"SA Langhans","year":"2018","unstructured":"Langhans SA (2018) Three-dimensional in vitro cell culture models in drug discovery and drug repositioning. Front Pharmacol 9:6","journal-title":"Front Pharmacol"},{"key":"10_CR32","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1007\/s10439-016-1640-4","volume":"45","author":"J Vanderburgh","year":"2017","unstructured":"Vanderburgh J, Sterling JA, Guelcher SA (2017) 3D printing of tissue engineered for in vitro modeling of disease progression and drug screening. Ann Biomed Eng 45:164\u2013179","journal-title":"Ann Biomed Eng"},{"key":"10_CR33","doi-asserted-by":"publisher","first-page":"107423","DOI":"10.18632\/oncotarget.22475","volume":"8","author":"N Jacobi","year":"2017","unstructured":"Jacobi N, Seeboeck R, Hofmann E et al (2017) Organotypic three-dimensional cancer cell cultures mirror drug responses in vivo: lessons learned from the inhibition of EGFR signaling. Oncotarget 8:107423\u2013107440","journal-title":"Oncotarget"},{"key":"10_CR34","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1177\/1087057117696795","volume":"22","author":"Y Fang","year":"2017","unstructured":"Fang Y, Eglen RM (2017) Three-dimensional cell cultures in drug discovery and development. SLAS Discov 22:456\u2013472","journal-title":"SLAS Discov"},{"key":"10_CR35","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/s12934-015-0383-5","volume":"14","author":"A Osswald","year":"2015","unstructured":"Osswald A, Sun Z, Grimm V et al (2015) Three-dimensional tumor spheroids for in vitro analysis of bacteria as gene delivery vectors in tumor therapy. Microb Cell Fact 14:199","journal-title":"Microb Cell Fact"},{"key":"10_CR36","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1016\/j.drudis.2016.04.010","volume":"21","author":"A Nyga","year":"2016","unstructured":"Nyga A, Neves J, Stamati K et al (2016) The next level of 3D tumour models: Immunocompetence. Drug Discov Today 21:1421\u20131428","journal-title":"Drug Discov Today"},{"key":"10_CR37","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.addr.2014.05.003","volume":"79\u201380","author":"C Hirt","year":"2014","unstructured":"Hirt C, Papadimitropoulos A, Mele V et al (2014) In vitro 3D models of tumor-immune system interaction. Adv Drug Deliv Rev 79\u201380:145\u2013154","journal-title":"Adv Drug Deliv Rev"},{"key":"10_CR38","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s00262-016-1927-1","volume":"66","author":"S Herter","year":"2017","unstructured":"Herter S, Morra L, Schlenker R et al (2017) A novel three-dimensional heterotypic spheroid model for the assessment of the activity of cancer immunotherapy agents. Cancer Immunol Immunother 66:129\u2013140","journal-title":"Cancer Immunol Immunother"},{"key":"10_CR39","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1186\/s12885-015-1321-y","volume":"15","author":"A Giannattasio","year":"2015","unstructured":"Giannattasio A, Weil S, Kloess S et al (2015) Cytotoxicity and infiltration of human NK cells in in vivo-like tumor spheroids. BMC Cancer 15:351","journal-title":"BMC Cancer"},{"key":"10_CR40","doi-asserted-by":"publisher","first-page":"383","DOI":"10.4049\/jimmunol.1700453","volume":"199","author":"D Masopust","year":"2017","unstructured":"Masopust D, Sivula CP, Jameson SC (2017) Of mice, dirty mice, and men: using mice to understand human immunology. J Immunol 199:383\u2013388","journal-title":"J Immunol"},{"key":"10_CR41","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1016\/j.cell.2016.05.082","volume":"165","author":"H Clevers","year":"2016","unstructured":"Clevers H (2016) Modeling development and disease with organoids. Cell 165:1586\u20131597","journal-title":"Cell"},{"key":"10_CR42","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.gde.2013.11.012","volume":"24","author":"N Sachs","year":"2014","unstructured":"Sachs N, Clevers H (2014) Organoid cultures for the analysis of cancer phenotypes. Curr Opin Genet Dev 24:68\u201373","journal-title":"Curr Opin Genet Dev"},{"key":"10_CR43","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s00109-017-1531-7","volume":"95","author":"S Bartfeld","year":"2017","unstructured":"Bartfeld S, Clevers H (2017) Stem cell-derived organoids and their application for medical research and patient treatment. J Mol Med (Berl) 95:729\u2013738","journal-title":"J Mol Med (Berl)"},{"key":"10_CR44","doi-asserted-by":"publisher","first-page":"1247125","DOI":"10.1126\/science.1247125","volume":"345","author":"MA Lancaster","year":"2014","unstructured":"Lancaster MA, Knoblich JA (2014) Organogenesis in a dish: modeling development and disease using organoid technologies. Science 345:1247125","journal-title":"Science"},{"key":"10_CR45","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/nature12517","volume":"501","author":"MA Lancaster","year":"2013","unstructured":"Lancaster MA, Renner M, Martin CA et al (2013) Cerebral organoids model human brain development and microcephaly. Nature 501:373\u2013379","journal-title":"Nature"},{"key":"10_CR46","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1038\/nprot.2014.158","volume":"9","author":"MA Lancaster","year":"2014","unstructured":"Lancaster MA, Knoblich JA (2014) Generation of cerebral organoids from human pluripotent stem cells. Nat Protoc 9:2329\u20132340","journal-title":"Nat Protoc"},{"key":"10_CR47","doi-asserted-by":"publisher","first-page":"28951","DOI":"10.1038\/srep28951","volume":"6","author":"K Stock","year":"2016","unstructured":"Stock K, Estrada MF, Vidic S et al (2016) Capturing tumor complexity in vitro: comparative analysis of 2D and 3D tumor models for drug discovery. Sci Rep 6:28951","journal-title":"Sci Rep"},{"key":"10_CR48","doi-asserted-by":"publisher","first-page":"170170","DOI":"10.1038\/sdata.2017.170","volume":"4","author":"R Hoogt de","year":"2017","unstructured":"de Hoogt R, Estrada MF, Vidic S et al (2017) Protocols and characterization data for 2D, 3D, and slice-based tumor models from the PREDECT project. Sci Data 4:170170","journal-title":"Sci Data"},{"key":"10_CR49","doi-asserted-by":"publisher","first-page":"17187","DOI":"10.1038\/srep17187","volume":"5","author":"EJ Davies","year":"2015","unstructured":"Davies EJ, Dong M, Gutekunst M et al (2015) Capturing complex tumour biology in vitro: histological and molecular characterisation of precision cut slices. Sci Rep 5:17187","journal-title":"Sci Rep"},{"key":"10_CR50","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.biomaterials.2018.02.030","volume":"163","author":"SP Rebelo","year":"2018","unstructured":"Rebelo SP, Pinto C, Martins TR et al (2018) 3D-3-culture: a tool to unveil macrophage plasticity in the tumour microenvironment. Biomaterials 163:185\u2013197","journal-title":"Biomaterials"},{"key":"10_CR51","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/291335a0","volume":"291","author":"CS Henney","year":"1981","unstructured":"Henney CS, Kuribayashi K, Kern DE et al (1981) Interleukin-2 augments natural killer cell activity. Nature 291:335\u2013338","journal-title":"Nature"},{"key":"10_CR52","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.4049\/jimmunol.155.3.1066","volume":"155","author":"G Bellone","year":"1995","unstructured":"Bellone G, Aste-Amezaga M, Trinchieri G et al (1995) Regulation of NK cell functions by TGF-beta 1. J Immunol 155:1066\u20131073","journal-title":"J Immunol"},{"key":"10_CR53","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1002\/eji.200939910","volume":"40","author":"DS Allan","year":"2010","unstructured":"Allan DS, Rybalov B, Awong G et al (2010) TGF-\u03b2 affects development and differentiation of human natural killer cell subsets. Eur J Immunol 40:2289\u20132295","journal-title":"Eur J Immunol"},{"issue":"12","key":"10_CR54","doi-asserted-by":"publisher","first-page":"3934","DOI":"10.4049\/jimmunol.1701461","volume":"200","author":"V Zaiatz-Bittencourt","year":"2018","unstructured":"Zaiatz-Bittencourt V, Finlay DK, Gardiner CM (2018) Canonical TGF-\u03b2 signaling pathway represses human NK cell metabolism. J Immunol 200(12):3934\u20133941","journal-title":"J Immunol"},{"key":"10_CR55","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/S0014-5793(04)00026-2","volume":"559","author":"RS Alli","year":"2004","unstructured":"Alli RS, Khar A (2004) Interleukin-12 secreted by mature dendritic cells mediates activation of NK cell function. FEBS Lett 559:71\u201376","journal-title":"FEBS Lett"},{"key":"10_CR56","doi-asserted-by":"crossref","first-page":"4738","DOI":"10.4049\/jimmunol.160.10.4738","volume":"160","author":"M Tomura","year":"1998","unstructured":"Tomura M, Zhou XY, Maruo S et al (1998) A critical role for IL-18 in the proliferation and activation of NK1.1+ CD3- cells. J Immunol 160:4738\u20134746","journal-title":"J Immunol"},{"key":"10_CR57","doi-asserted-by":"publisher","first-page":"4611","DOI":"10.1073\/pnas.84.13.4611","volume":"84","author":"G Jung","year":"1987","unstructured":"Jung G, Ledbetter JA, M\u00fcller-Eberhard HJ (1987) Induction of cytotoxicity in resting human T lymphocytes bound to tumor cells by antibody heteroconjugates. Proc Natl Acad Sci U S A 84:4611\u20134615","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10_CR58","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.4049\/jimmunol.144.5.1646","volume":"144","author":"LA Turka","year":"1990","unstructured":"Turka LA, Ledbetter JA, Lee K et al (1990) CD28 is an inducible T cell surface antigen that transduces a proliferative signal in CD3+ mature thymocytes. J Immunol 144:1646\u20131653","journal-title":"J Immunol"},{"key":"10_CR59","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-1759(90)90210-M","volume":"128","author":"SR Riddell","year":"1990","unstructured":"Riddell SR, Greenberg PD (1990) The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells. J Immunol Methods 128:189\u2013201","journal-title":"J Immunol Methods"}],"container-title":["Methods in Molecular Biology","Target Identification and Validation in Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-4939-9145-7_10","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T21:21:32Z","timestamp":1694726492000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-1-4939-9145-7_10"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"ISBN":["9781493991440","9781493991457"],"references-count":59,"URL":"https:\/\/doi.org\/10.1007\/978-1-4939-9145-7_10","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019]]},"assertion":[{"value":"26 March 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}